A multi-institution study of molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes
Latest Information Update: 08 Jul 2021
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Vemurafenib (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.